21-45989626-G-A
Variant summary
Our verdict is Pathogenic. Variant got 22 ACMG points: 22P and 0B. PS1PM1PM2PM5PP3_StrongPP5_Very_Strong
The ENST00000361866.8(COL6A1):c.877G>A(p.Gly293Arg) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 13/21 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another nucleotide change resulting in same amino acid change has been previously reported as Pathogenicin ClinVar. Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G293E) has been classified as Pathogenic.
Frequency
Consequence
ENST00000361866.8 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 22 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
COL6A1 | NM_001848.3 | c.877G>A | p.Gly293Arg | missense_variant | 10/35 | ENST00000361866.8 | NP_001839.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
COL6A1 | ENST00000361866.8 | c.877G>A | p.Gly293Arg | missense_variant | 10/35 | 1 | NM_001848.3 | ENSP00000355180 | P1 |
Frequencies
GnomAD3 genomes Cov.: 34
GnomAD4 exome Cov.: 43
GnomAD4 genome Cov.: 34
ClinVar
Submissions by phenotype
not provided Pathogenic:7
Likely pathogenic, no assertion criteria provided | clinical testing | Clinical Genetics, Academic Medical Center | - | - - |
Pathogenic, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, Amsterdam University Medical Center | - | - - |
Pathogenic, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Dec 30, 2015 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Sep 21, 2022 | Reported to segregate with disease in affected individuals from two unrelated families in published literature (Kim et al., 2012; Cruz et al., 2016); Replaces the glycine in the canonical Gly-X-Y repeat of the triple helical domain and is expected to disrupt normal protein folding and function, which is an established mechanism of disease (HGMD); Not observed in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 31561939, 27854213, 28688748, 28831785, 27363342, 30808312, 32065942, 20976770, 26867126, 22975586, 19344236, 15689448, 24223098, 33146414, 31069529, 33441455, 24038877, 34167565, 25473036, 27159402, 33726816, 29419890, 22075033, 35457228) - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Feb 16, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Aug 01, 2020 | - - |
Bethlem myopathy 1A Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Kasturba Medical College, Manipal, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, India | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 05, 2023 | This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 293 of the COL6A1 protein (p.Gly293Arg). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with autosomal dominant Bethlem myopathy and Ullrich congenital muscular dystrophy (PMID: 20976770, 22075033, 22975586, 24038877, 24223098, 26867126, 27363342, 27854213). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 93895). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt COL6A1 protein function with a positive predictive value of 80%. This variant disrupts the triple helix domain of COL6A1. Glycine residues within the Gly-Xaa-Yaa repeats of the triple helix domain are required for the structure and stability of fibrillar collagens (PMID: 7695699, 8218237, 19344236). In COL6A1, variants at these glycine residues are significantly enriched in individuals with autosomal dominant disease (PMID: 15689448, 24038877) compared to the general population (ExAC). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | 3billion | May 22, 2022 | The variant is not observed in the gnomAD v2.1.1 dataset. The variant is located in a mutational hot spot and/or well-established functional domain in which established pathogenic variants have been reported. In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.99; 3Cnet: 0.99). Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000093895). The variant has been observed in multiple (>3) similarly affected unrelated individuals (PMID: 20976770, 22075033, 22975586, 24038877, 24223098, 26867126, 27363342, 27854213). Different missense changes at the same codon (p.Gly293Glu, p.Gly293Val) have been reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000639559, VCV000944129). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline. - |
Ullrich congenital muscular dystrophy 1A;CN029274:Bethlem myopathy 1A Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Jan 21, 2022 | - - |
Collagen 6-related myopathy Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | DASA | Jan 05, 2022 | The c.877G>A;p.(Gly293Arg) missense variant has been observed in affected individual(s) and ClinVar contains an entry for this variant (Clinvar ID: 93895; PMID: 27854213; 26867126; 24223098; 24038877; 22975586; 22075033) - PS4. Same amino acid change as a previously established pathogenic variant regardless of nucleotide change(Clinvar ID: 1076562) - PS1. The variant is located in a mutational hot spot and/or critical and well-established functional domain (Collagen; PMID: 24038877) - PM1. This variant is not present in population databases (rs398123643, gnomAD; ABraOM no frequency - http://abraom.ib.usp.br/) - PM2. Pathogenic missense variant in this residue have been reported (ClinVar ID: 944129; 639559) - PM5. The variant was assumed de novo, but without confirmation of paternity and maternity (PMID: 22975586) - PM6. Multiple lines of computational evidence support a deleterious effect on the gene or gene product - PP3. In summary, the currently available evidence indicates that the variant is pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at